肝细胞癌患者TACE治疗前后血清miR-145水平变化及其临床意义

doi:10.3969/j.issn.1672-5069.2020.02.029

摘要/Abstract

摘要： 目的探讨肝细胞癌(HCC)患者在经导管动脉化疗栓塞术(TACE)治疗前后血清microRNA-145(miR-145)水平变化及其临床意义。方法 2013年1月～2015年12月我院收治的72例HCC患者和同期60例健康体检者,采用qRT-PCR法检测血清miR-145水平,采用ROC曲线分析血清miR-145和甲胎蛋白(AFP)预测不良预后的价值。结果在治疗1个月末,16例(22.2 %)为PR,13例(18.1%)为SD,43例(59.7 %)为PD;HCC组血清miR-145水平为(0.59±0.25),显著低于对照组【(1.02±0.28),P＜0.05】,术后1个月,HCC患者血清miR-145水平为(0.81±0.26),显著高于术前(P＜0.05);不同性别、年龄、肿瘤直径、肿瘤分化、癌栓和Child-Pugh分级患者血清miR-145水平无显著性差异(P＞0.05),而不同TNM分级和术前AFP水平患者之间差异显著(P＜0.05); PD组血清miR-145水平为(0.86±0.21),显著高于PR组或SD组【分别为(0.62±0.19)和(0.75±0.19),P＜0.05】;随访3年,28例(38.9%)患者死亡,其中高miR-14 水平患者3 a生存率为75.6 %,显著高于低水平患者的41.9 %(x²=8.765,P＜0.05);血清miR-145、AFP和miR-145联合AFP预测HCC不良预后的曲线下面积分别为0.871、0.851和0.942,两者联合预测的敏感度为91.7 %,准确度为90.2%。结论 TACE术后检测血清miR-145水平可能预示HCC患者预后较好。

关键词: 肝细胞癌, miR-145, 经导管动脉化疗栓塞术, 预后

Abstract: Objective The aim of this study was to investigate the significance of blood miR-145 levels in patients with hepatocellular carcinoma (HCC) after transcatheter arterial chemoembolization (TACE) treatment. Methods 72 patients with HCC and 60 healthy persons were recruited in our hospital between January 2013 and December 2015, and blood miR-145 levels were detected by qRT-PCR. The diagnostic performance of serum miR-145 and alpha-fetoprotein (AFP) in predicting prognosis were compared by ROC curve analysis. Results One month after TACE treatment, 16 patients (22.2%) got PR, 13 patients (18.1%) got SD, and 43 patients (59.7%) got PD results; the blood miR-145 level in patients with HCC was (0.59±0.25) , significantly lower than [(1.02±0.28), P < 0.05] in the control, and blood miR-145 level in the HCC group 1 month after TACE was (0.81±0.26) , significantly increased as compared to that before TACE (P< 0.05); the blood miR-145 levels in patients with HCC were related to TNM grades and preoperative serum AFP level (P<0.05); the miR-145 level in patients with PD response was (0.86±0.21) , significantly higher than [(0.62±0.19) or (0.75±0.19), respectively, P<0.05] in patients with PR or SD; at the end of 3 year follow-up, 28 patients (38.9%)died; the 3 annual overall survival rate in HCC patients with high level of miR-14 was 75.6%, significantly higher than 41.9% in patients with low miR-14 level (x²=8.765, P< 0.05); the areas under the ROC of blood miR-145, serum AFP and miR-145 plus AFP in predicting the poor prognosis of patients with HCC were 0.871, 0.851 and 0.942, respectively, with the sensitivity and accuracy of combined prediction being 91.67% and 90.15%, respectively. Conclusion The detection of blood miR-145 might predict the prognosis of patients with HCC after TACE, which needs further investigation.

Key words: Hepatocellular carcinoma, miR-145, Transcatheter arterial chemoembolization, Prognosis

李天纵, 周松, 周石. 肝细胞癌患者TACE治疗前后血清miR-145水平变化及其临床意义[J]. 实用肝脏病杂志, 2020, 23(2): 264-267.

Li Tianzong, Zhou Song, Zhou Shi. Significance of blood miR-145 in patients with hepatocellular carcinoma after TACE treatment[J]. Journal of Practical Hepatology, 2020, 23(2): 264-267.

参考文献

[1] 盛须仁, 邢松歌, 葛勇胜,等. TUSC3基因在肝细胞癌中的水平及其临床意义. 中国普通外科杂志, 2018,27(1):75-80.
[2] Xu Y, An Y, Wang Y, et al. MiR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep, 2013, 29(5):2019-2024.
[3] Du K, Gong H Y, Gong Z M. Influence of serum VEGF levels on therapeutic outcome and diagnosis/prognostic value in patients with cervical cancer. Asian Pacif J Cancer Prevent, 2014, 15(20):8793-8796.
[4] Song B, Chung Y, Kim J A, et al. Association between insulin-like growth factor-2 and metastases after transcatheter arterial chemoembolization in patients with hepatocellular carcinoma. Cancer, 2015, 91(12):2386-2393.
[5] 嘉妍, 宋金云, 王建芳,等. AFP、CA19-9、CEA联合检测对原发性肝癌的早期诊断价值. 临床肝胆病杂志, 2017, 33(7):1291-1295.
[6] Lupini L, Pepe F, Ferracin M, et al. Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma. Oncotarget, 2016, 7(21):31361-31371.
[7] 中华人民共和国卫生和计划生育委员会医政医管局, 朱红梅. 原发性肝癌诊疗规范(2017年版). 中华肝脏病杂志, 2017, 25(25):886-895.
[8] 李虎子, 贾英杰, 孔凡铭,等. 改良RECIST标准更适用经TACE治疗的肝癌患者的预后评价. 介入放射学杂志, 2016, 25(1):29-33.
[9] O'Conor G T, Tatarinov Y S, Abelev G I, et al. A collaborative study for the evaluation of a serologic test for primary liver cancer. Cancer, 2015, 25(5):1091-1098.
[10] 房锋, 宋天强. 微小RNA在肝细胞癌中的相关研究进展. 中国普通外科杂志, 2018, 27(7):103-113.
[11] 左芳, 朱中梁, 汪宏良. 肝细胞癌组织miRNA-155水平变化及其对预后的影响. 实用肝脏病杂志, 2018, 21(1):92-95.
[12] 徐晓宏, 高守宝, 王玥,等. miRNA水平与免疫细胞因子相关性在原发性肝癌早期诊断和预后中的作用中国免疫学杂志, 2018,34(1):104-108.
[13] 刘洪璐, 王熙才. 外周血miRNA应用于肿瘤早期诊断的研究进展. 中国肿瘤生物治疗杂志, 2018,25(2):109-117.
[14] Ding W, Tan H, Zhao C, et al. MiR-145 suppresses cell proliferation and motility by inhibiting ROCK1 in hepatocellular carcinoma. Tumour Biol, 2016, 37(5):6255-6260.
[15] 杨海青, 孙伟娜. TACE治疗原发性肝癌患者血清肿瘤标志物水平变化. 实用肝脏病杂志, 2018, 21(1):123-124.
[16] Yao Z, Dong Y, Wu G, et al. Preoperative diagnosis and prediction of hepatocellular carcinoma: Radiomics analysis based on multi-modal ultrasound images. BMC Cancer, 2018,18(1):1089.
[17] Van Tong H, Van Ba N, Hoan NX, et al. Soluble fibrinogen-like protein 2 levels in patients with hepatitis B virus-related liver diseases. BMC Infect Dis, 2018,18(1):553.
[18] Wu H, Zhao W, Zhang J,et al. Clinical characteristics of hepatic Arterioportal shunts associated with hepatocellular carcinoma. BMC Gastroenterol, 2018, 18(1):174.
[19] Božin T, Mustapić S, Bokun T, et al. Albi score as a predictor of survival in patients with compensated cirrhosis resected for hepatocellular carcinoma: exploratory evaluation in relationship to Palbi and Meld liver function scores. Acta Clin Croat, 2018, 57(2):292-300.
[20] Li Z, Wang Y, Duan S,et al. Expression of TBX3 in hepatocellular carcinoma and Its Clinical Implication. Med Sci Monit,2018,24:9324-9333.